Literature DB >> 9670945

Carrier-induced, hapten-specific suppression: a problem of antigen presentation?

X Renjifo1, S Wolf, P P Pastoret, H Bazin, J Urbain, O Leo, M Moser.   

Abstract

Prior immunity against a carrier protein has been shown to modulate the serologic response to injected haptens attached to the same carrier. In particular, a carrier/hapten-carrier immunization protocol induces marked suppression for IgG2a anti-hapten Ab production but does not interfere with anti-carrier Ab responses. Although the phenomenon of epitopic suppression has been amply demonstrated, the mechanism underlying the suppression remains unknown. The selective deficiency in IgG2a secretion suggests that IFN-gamma-producing Th1 cells are not properly activated. We and others have shown that the nature of the APCs present during the first encounter with the Ag influences the development of selected Th populations in vivo; dendritic cells (DCs) seem to be required for the induction of primary, Th1-type responses. Since carrier priming induces the clonal expansion of specific B cells that appear to efficiently capture the Ag, we hypothesized that the hapten-carrier conjugate may be presented by B cells in preimmunized animals. Therefore, we immunized mice to the conjugate by injecting syngeneic DCs pulsed in vitro with the Ag. Our data show that an injection of DCs and IL-12 prevents epitopic suppression, suggesting that it may result from defective Ag presentation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9670945

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

1.  Combined conjugate vaccines: enhanced immunogenicity with the N19 polyepitope as a carrier protein.

Authors:  Karin Baraldo; Elena Mori; Antonella Bartoloni; Francesco Norelli; Guido Grandi; Rino Rappuoli; Oretta Finco; Giuseppe Del Giudice
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

Review 2.  Protein carriers of conjugate vaccines: characteristics, development, and clinical trials.

Authors:  Michael E Pichichero
Journal:  Hum Vaccin Immunother       Date:  2013-08-16       Impact factor: 3.452

3.  The efficient isolation of murine splenic dendritic cells and their cytochemical features.

Authors:  Amir Hassan Zarnani; Seyyed-Mohammad Moazzeni; Fazel Shokri; Mojdeh Salehnia; Pouneh Dokouhaki; Jaleh Shojaeian; Mahmood Jeddi-Tehrani
Journal:  Histochem Cell Biol       Date:  2006-04-11       Impact factor: 4.304

4.  Humoral hyporesponsiveness to a conjugate contraceptive vaccine and its bypass by diverse carriers using permissible adjuvant.

Authors:  A Mandokhot; R Pal; S Nagpal; V S Chauhan; S Ahlawat; O Singh
Journal:  Clin Exp Immunol       Date:  2000-10       Impact factor: 4.330

5.  Stable production of peptide antigens in transgenic tobacco chloroplasts by fusion to the p53 tetramerisation domain.

Authors:  Susana M Ortigosa; Alicia Fernández-San Millán; Jon Veramendi
Journal:  Transgenic Res       Date:  2009-12-02       Impact factor: 2.788

6.  Insight into the potential for DNA idiotypic fusion vaccines designed for patients by analysing xenogeneic anti-idiotypic antibody responses.

Authors:  Francesco Forconi; Catherine A King; Surinder S Sahota; Christopher K Kennaway; Nigel H Russell; Freda K Stevenson
Journal:  Immunology       Date:  2002-09       Impact factor: 7.397

7.  Strategies to alleviate original antigenic sin responses to influenza viruses.

Authors:  Jin Hyang Kim; William G Davis; Suryaprakash Sambhara; Joshy Jacob
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-06       Impact factor: 11.205

8.  Physicochemical characterisation, immunogenicity and protective efficacy of a lead streptococcal vaccine: progress towards Phase I trial.

Authors:  Manisha Pandey; Jessica Powell; Ainslie Calcutt; Mehfuz Zaman; Zachary N Phillips; Mei Fong Ho; Michael R Batzloff; Michael F Good
Journal:  Sci Rep       Date:  2017-10-23       Impact factor: 4.379

9.  Glycoconjugates: What It Would Take To Master These Well-Known yet Little-Understood Immunogens for Vaccine Development.

Authors:  Fikri Avci; Francesco Berti; Peter Dull; John Hennessey; Viliam Pavliak; A Krishna Prasad; Willie Vann; Michael Wacker; Olivier Marcq
Journal:  mSphere       Date:  2019-09-25       Impact factor: 4.389

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.